Submit a Letter to the Editor for:
Rupert Kaul, Tao Dong, Francis A. Plummer, Joshua Kimani, Timothy Rostron, Peter Kiama, Ephantus Njagi, Erastus Irungu, Bashir Farah, Julius Oyugi, Rana Chakraborty, Kelly S. MacDonald, Job J. Bwayo, Andrew McMichael, Sarah L. Rowland-Jones
J Clin Invest. 2001;
107(10):1303
doi:10.1172/JCI12433
Abstract |
Full text
|
PDF
H
IV-1–specific cytotoxic T-lymphocyte (CTL) responses have been detected at a low frequency in many HIV-1–exposed, persistently seronegative (HEPS) subjects. However, it is unclear how CTLs could protect against HIV acquisition in HEPS subjects, when high levels of circulating CTL fail to prevent disease progression in most seropositive subjects. To address this issue we studied CD8+ lymphocyte responses to a panel of HIV-1 CTL epitopes in 91 HEPS and 87 HIV-1–infected Nairobi sex workers. HIV-specific responses in seropositive women focused strongly on epitopes rarely or never recognized in HEPS subjects, who targeted epitopes that were subdominant or unrecognized in infected women. These differences in epitope specificity were restricted by only those HLA class I alleles that are associated with a reduced risk of HIV-1 infection in this cohort. Late seroconversion in HEPS donors was associated with a switch in epitope specificity and/or immunodominance to those epitopes preferentially recognized by HIV-1–infected women. The likelihood of detecting HIV-1–specific responses in HEPS women increased with the duration of viral exposure, suggesting that HIV-1–specific CD8+ responses are acquired over time. The association between differential recognition of distinct CTL epitopes and protection from HIV-1 infection may have significant implications for vaccine design.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
